$FTH 4/A SEC Filings

Filed On	Filing
16 Jun 2026	Form 4/A: Parikh Anand Kiran, Director Granted 761.428 Series B Preferred Stock · Granted 149,204 Employee Stock Option (right to buy)
29 Mar 2023	Form 4/A: Colgan Erin, Chief Financial Officer Received 51,346 shares as a grant or award · Granted 90,000 Stock Option (Right to Buy)
29 Mar 2023	Form 4/A: Celebi John, Director Received 73,193 shares as a grant or award · Granted 90,000 Stock Option (Right to Buy)
29 Mar 2023	Form 4/A: Gallagher Patrick Stephen, Chief Business Officer Received 43,513 shares as a grant or award · Granted 60,000 Stock Option (Right to Buy)
07 Mar 2023	Form 4/A: Cambrian BioPharma Inc, 10% owner Received 4,466 shares as a grant or award · Granted 14,550 Stock Option (right to buy)
01 Sep 2022	Form 4/A: Pierce Robert Hamilton, Chief R&D Officer Holds 94,463 shares of Common Stock
01 Aug 2022	Form 4/A: Peyer James, Director Received 4,466 shares as a grant or award · Granted 14,550 Stock Option (right to buy)
10 Jun 2022	Form 4/A: Peyer James, Director Bought 1,203 shares ($3.85K)
10 Jun 2022	Form 4/A: Cambrian BioPharma Inc, 10% owner Bought 1,203 shares ($3.85K)
21 Apr 2022	Form 4/A: Peyer James, Director Bought 9,500 shares ($136K)
21 Apr 2022	Form 4/A: Peyer James, Director Bought 752 shares ($14.9K)
21 Apr 2022	Form 4/A: Cambrian BioPharma Inc, 10% owner Bought 9,500 shares ($136K)
21 Apr 2022	Form 4/A: Cambrian BioPharma Inc, 10% owner Bought 752 shares ($14.9K)

Comments